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Abstract
Introduction Insulin-like growth factor binding protein-3
(IGFBP-3) differentially modulates breast epithelial cell growth
through insulin-like growth factor (IGF)-dependent and IGF-
independent pathways and is a direct (IGF-independent) growth
inhibitor as well as a mitogen that potentiates EGF (epidermal
growth factor) and interacts with HER-2. Previously, high
IGFBP-3 levels in breast cancers have been determined by
enzyme-linked immunosorbent assay and immunoradiometric
assay methods. In vitro, IGFBP-3's mechanisms of action may
involve cell membrane binding and nuclear translocation. To
evaluate tumour-specific IGFBP-3 expression and its subcellular
localisation, this study examined immunohistochemical IGFBP-3
expression in a series of invasive ductal breast cancers (IDCs)
with synchronous ductal carcinomas in situ (DCIS) in relation to
clinicopathological variables and patient outcome.
Methods Immunohistochemical expression of IGFBP-3 was
evaluated with the sheep polyclonal antiserum (developed in
house) with staining performed as described previously.
Results IGFBP-3 was evaluable in 101 patients with a variable
pattern of cytoplasmic expression (positivity of 1+/2+ score) in
85% of invasive and 90% of DCIS components. Strong (2+)
IGFBP-3 expression was evident in 32 IDCs and 40 cases of
DCIS. A minority of invasive tumours (15%) and DCIS (10%)
lacked IGFBP-3 expression. Nuclear IGFBP-3 expression was
not detectable in either invasive cancers or DCIS, with a
consistent similarity in IGFBP-3 immunoreactivity in IDCs and
DCIS. Positive IGFBP-3 expression showed a possible trend in
association with increased proliferation (P = 0.096), oestrogen
receptor (ER) negativity (P = 0.06) and HER-2 overexpression
(P = 0.065) in invasive tumours and a strong association with
ER negativity (P  = 0.037) in DCIS. Although IGFBP-3
expression was not an independent prognosticator, IGFBP-3-
positive breast cancers may have shorter disease-free and
overall survivals, although these did not reach statistical
significance.
Conclusions Increased breast epithelial IGFBP-3 expression is
a feature of tumorigenesis with cytoplasmic immunoreactivity in
the absence of significant nuclear localisation in IDCs and
DCIS. There are trends between high levels of IGFBP-3 and
poor prognostic features, suggesting that IGFBP-3 is a potential
mitogen. IGFBP-3 is not an independent prognosticator for
overall survival or disease-free survival, to reflect its dual effects
on breast cancer growth regulated by complex pathways in vivo
that may relate to its interactions with other growth factors.
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Introduction
Insulin-like growth factors (IGF-I and IGF-II) regulate the
cellular growth of normal and malignant breast epithelial
cells with a role in malignant transformation [1-3]. IGFs are
potent mitogens and are synergistic with oestrogen and
epidermal growth factor (EGF) to stimulate cellular
cc = Spearman correlation coefficient; DCIS = ductal carcinoma in situ; DFS = disease-free survival; ER = oestrogen receptor; GPG = good prog-
nostic group; HPF = high-power field; IDC = invasive ductal cancer; IGF = insulin-like growth factor; IGFBP-3 = insulin-like growth factor binding 
protein-3; IHC = immunohistochemistry; MAPK = mitogen-activated protein kinase; MPG = moderate prognostic group; NPI = Nottingham Prognos-
tic Index; OS = overall survival; PPG = poor prognostic group; TBS = Tris-buffered saline; VNPC = Van Nuys Pathologic Classification.Breast Cancer Research    Vol 7 No 1    Vestey et al.
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proliferation[4]. The IGFs are modulated by a family of six
high-affinity IGF binding proteins, of which IGFBP-3 pre-
dominates in serum and is upregulated in breast cancer cell
lines, including breast epithelium [1,5,6]. Both IGFs (IGF-I
and IGF-II) have a preferential stromal expression and
together with epithelial IGFBP-3 have a significant para-
crine influence on breast epithelial growth [1,7]. IGFBPs
have multiple and complex functions that can be either IGF
dependent or IGF independent. With respect to IGF-
dependent function, IGFBP-3 preferentially binds IGFs to
either inhibit or activate IGF mitogenic effects in vitro,
through blocking the IGF-receptor interaction, in contrast
to a prolongation of IGFs' half-life and their protection from
degradation [1-3]. IGFBP-3 is pro-apoptotic in an IGF-
dependent manner, as well as an IGF-independent manner,
and enhances the p53 DNA damage response in vitro
[8,9]. The particular significance of IGFBP-3 in regulating
epithelial cell growth has been highlighted because the
actions of many growth inhibitors, apoptotic agents and
anti-cancer treatments (transforming growth factor-β, retin-
oids, p53 and anti-oestrogens) are, at least in part, medi-
ated by their ability to stimulate local IGFBP-3 production
[1-3].
Through complex and as yet poorly understood mecha-
nisms, IGFBP-3 is a direct (IGF-independent) growth inhib-
itor as well as a mitogen on breast epithelial cells[10,11].
Further, IGFBP-3 inhibits oestradiol-stimulated cell prolifer-
ation in breast cancer cell lines, with the potential to accen-
tuate ceramide and paclitaxel-induced apoptosis directly
[12-14]. By contrast, accumulating evidence in vitro sug-
gests the potential mitogenicity of IGFBP-3 through its
interactions with EGF receptor (EGFR) and Ras-p44/42
mitogen-activated protein kinase (MAPK) signalling in
breast epithelial cells [15-18]. Postulated mechanisms for
IGFBP-3's direct intrinsic actions on cell growth and apop-
tosis have not as yet characterised a definitive cell mem-
brane receptor or the necessity for IGFBP-3 cell surface
interaction or nuclear translocation[19]. Intracellular traf-
ficking of IGFBP-3 with nuclear localisation in T47D breast
cancer cells is explicable through a carboxy-terminal
nuclear localisation signal and importin-β-mediated nuclear
transport[15,20,21]. At present, the functional implications
of nuclear IGFBP-3 are unknown[22].
Complex IGFBP-3 modulation of breast cancer growth has
prompted several studies to examine levels of IGFBP-3 in
breast cancer tissues in relation to clinicopathological char-
acteristics and patient outcome [23-26]. Circulating
IGFBP-3 may avert breast cancer development, with the
clinical paradox that increasing IGFBP-3 levels in breast
tumours may indicate adverse prognostic cancers [2,23-
26]. This reflects the complexity of IGFBP-3 effects on cell
proliferation and its potential role as a mitogen as well as a
growth inhibitor. Poor prognostic tumours with increasing
IGFBP-3 expression may relate to recent evidence in vitro
in which the pro-apoptotic action of IGFBP-3 is reversed by
the extracellular matrix protein fibronectin[27,28]. In keep-
ing with these findings, high levels of fibronectin expression
are associated with poor prognostic breast cancers [6,29].
IGFBP-3 interacts with integrin-receptor signalling with
modulation by fibronectin to increase cell attachment and
possible resistance to apoptosis[27].
The aim of this first immunohistochemical study was to
evaluate breast epithelial IGFBP-3 expression in relation to
clinicopathological parameters and prognosis in breast
cancer. IGFBPs are upregulated in malignant breast epi-
thelial cells with evidence in vivo that IGFBP-5 is overex-
pressed in the cytoplasm of breast cancers and their lymph
node metastases on tissue microassay immunohistochem-
istry (IHC)[6]. Accumulating evidence in vitro supports the
dual effects of IGFBP-3 on the cellular growth of breast
epithelial cells to emphasise the importance of selectively
analysing breast epithelial IGFBP-3 expression in compari-
son with the stroma. By contrast, previous studies have col-
lectively assessed breast epithelial and stromal IGFBP-3
levels by using immunoassay and immunoblot or ligand blot
methods [23-26]. Moreover, both the histological location
of IGFBP-3 and variations in its immunoreactivity have been
compared in this series of invasive ductal breast cancers
with concomitant evaluation of IGFBP-3 expression in syn-
chronous ductal carcinoma in situ (DCIS) within the same
tumour specimens. Increasing IGFBP-3 levels in breast
tumours may indicate adverse prognostic cancers, with
contradictory implications on patient outcomes[24,25] to
reflect the complexity of IGFBP-3 effects on cell prolifera-
tion[27,28,30]. We have shown a varying pattern of epithe-
lial IGFBP-3 cytoplasmic expression (1+/2+ score) in 85%
of invasive ductal cancers (IDCs) and 90% of DCIS com-
ponents, without detectable nuclear immunoreactivity.
Increasing levels of IGFBP-3 expression showed a trend
with increased proliferation, oestrogen receptor (ER) nega-
tivity and HER-2 overexpression to suggest its association
with poor prognostic tumours.
Methods
Patients
The study included 103 patients aged from 26 to 88 years
(median 59 years) with IDC of the breast, in association
with concomitant DCIS diagnosed between 1996 and
2000 at the Bristol Royal Infirmary, Bristol, UK (Table 1).
Patient numbers in clinicopathological subgroups reflect
those in whom IGFBP-3 was evaluable. Regional Ethics
Committee approval was granted before the start of the
study. Axillary lymphadenopathy was evaluable in 88
patients; 37 (42%) were lymph-node-negative and 51
(58%) were lymph-node-positive (N1, mobile ipsilateral, or
N2, fixed ipsilateral) patients. No axillary surgery was under-
taken in the remaining 13 patients because of age-relatedAvailable online http://breast-cancer-research.com/content/7/1/R119
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Table 1
Relationship between IGFBP-3 expression and clinicopathology
Characteristic IGFBP-3 score P No. of patients
Negative Weak (1+) Strong (2+)
I n v a s i v e  t u m o u r s 1 55 43 2 1 0 1 *
Age (years)
≤ 50 1 13 13 0.04 27
> 50 14 41 19 74
Lymph node status
Negative 7 17 13 0.216 37
Positive 4 31 16 51
Not assessed 13
IDC grade
I 2 9 5 0.836 16
II 9 24 17 50
III 4 21 10 35
IDC size
≤ 2 cm 9 26 17 0.720 52
>2 cm 6 27 14 47
Multifocal 2
LV invasion
Absent 9 27 12 0.411 48
Present 6 26 18 50
Not assessed 3
NPI
GPG (< 3.4) 6 17 11 0.662 34
MPG (3.4–5.4) 4 19 13 36
PPG (> 5.4) 1 11 4 16
Not calculable 15
ER (quick-score)
P o s i t i v e  ( 4 – 8 ) 1 22 82 1 0 . 0 66 1
Negative (0–3) 2 24 9 35
Not assessed 7
HER-2 IHC
Negative (0/1+) 14 48 23 0.065 85
Positive (2+/3+) 1 6 9 16
Ki67 IHC
Low proliferation < 10% 10 26 13 0.249 49
High proliferation ≥ 10% 5 28 19 52
DCIS 102*
VNPCBreast Cancer Research    Vol 7 No 1    Vestey et al.
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co-morbidity. Clinicopathological subgroups were ana-
lysed in accordance with the Nottingham Prognostic Index
(NPI) and divided into good (GPG), moderate (MPG) and
poor (PPG) prognostic groups as described, with a modifi-
cation that included no assessment of the internal mam-
mary lymph nodes[31]. Evaluation of the NPI was
precluded in 15 patients because of non-evaluable regional
lymphadenopathy and tumour size. Similarly, subgroups of
DCIS were analysed in accordance with the Van Nuys
Pathologic Classification (VNPC) (Table 1), which was not
assessable in five patients [32]. The design of the study to
include tumour representative samples of synchronous IDC
and DCIS precluded the analysis of the Van Nuys Prognos-
tic Index[32]. Adjuvant treatment groups comprised the fol-
lowing: tamoxifen in 60 patients (27 GPG, 16 MPG, 4 PPG
and 13 no NPI), and CMF-containing and anthracycline-
containing regimes in 17 and 21 patients, respectively (4
GPG, 19 MPG, 13 PPG and 2 no NPI). Five patients
received no adjuvant treatment. The median follow-up dura-
tion was 51 months (range 4–120 months). All were pri-
mary tumours with the exception of six local tumour
recurrences, which were excluded from the analysis of
patient outcome (see Table 3 and Fig. 2).
Tumour samples were collected and freshly fixed in buff-
ered formalin in accordance with a standardised protocol at
a single institution. Tumours were classified in accordance
with NHSBSP guidelines [33]. Invasive ductal carcinomas
were graded by the modified Bloom's grading system
described by Elston and Ellis[34]. ER immunostaining was
performed with a standard three-layered streptavidin-avi-
din-biotin horseradish peroxidase method with a mouse
anti-human ER primary antibody (M0747, 1:100 dilution;
DAKO, Ely, Cambridgeshire, UK) and a biotinylated rabbit
anti-mouse secondary antibody (E354, 1:350 dilution;
DAKO). Expression of ER was assessed with the quick-
score (0–8) and classified as positive (4–8; >3) or negative
(0–3; ≤ 3) in five high-power fields (HPFs) [35]. Tumour
proliferation was assessed with nuclear Ki67 immunostain-
ing (polyclonal rabbit anti-human Ki67 antigen; A0047,
1:100 dilution; DAKO). A goat anti-rabbit biotin-labelled
polypeptide (E432, 1:400 dilution; DAKO, Glostrup, Den-
mark) was used as a secondary antibody.
Tonsillar tissue was used as a positive control and primary
antibody was replaced with Tris-buffered saline (TBS) as a
negative control. Ki67 staining was evaluated as
percentage of positive tumour cells, with low proliferation
indicative of <10% of positive-staining cells, compared
with high proliferation with ≥ 10% positivity [36]. HER-2
immunostaining was performed with the mouse mono-
clonal anti-HER-2 antibody (RTU-CB11; Novocastra/Vec-
tor, Newcastle upon Tyne, UK), and the Envision Plus HRP
system (K4006; DAKO). HER-2 expression was scored
according to the degree and proportion of membrane stain-
ing, with a score of 0 or 1+ defined as negative, and 2+ or
3+ as HER-2 positive[37]. Lymphovascular invasion was
assessed as present or not, and together with ER, HER-2
Grade I 1 14 8 0.586 23
Grade II 5 17 14 36
Grade III 2 21 15 38
Not assessed 5
ER (quick-score)
P o s i t i v e  ( 4 – 8 ) 1 12 61 9 0.037 56
Negative (0–3) 1 23 9 33
Not assessed 13
HER-2 IHC
Negative (0/1+) 7 41 28 0.876 76
Positive (2+/3+) 2 9 8 19
Not assessed 7
Ki67 IHC
Low proliferation < 10% 6 30 24 0.972 60
High proliferation ≥ 10% 4 22 16 42
DCIS, ductal carcinoma in situ; ER, oestrogen receptor; GPG, good prognostic group; IHC, immunohistochemistry; MPG, moderate prognostic 
group; NPI, Nottingham Prognostic Index; PPG, poor prognostic group; VNPC, Van Nuys Pathologic classification. Significant P values (P < 0.05) 
are indicated in bold.
*Patient numbers reflect those in whom IGFBP-3 was evaluable.
Table 1 (Continued)
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and Ki67 was analysed in the Department of Pathology (by
CS and CC).
Immunohistochemistry
IGFBP-3 immunoreactivity was evaluated with the in-house
sheep polyclonal antiserum (Professor JMP Holly, IGF
Research Group, University of Bristol, Bristol, UK) at 1:800
dilution[9]. IGFBP-3 immunostaining of IDC and DCIS was
compared with formalin-fixed normal liver tissue as a posi-
tive control for IGFBP-3, and a replacement of the primary
antibody with TBS as a negative control. Validation and
specificity of the sheep polyclonal in-house antiserum has
previously been demonstrated with an IGFBP-3 peptide on
immunocytochemistry of Hs578T breast cancer cells[38].
Formalin-fixed paraffin sections of breast cancer tissue and
normal liver tissue were mounted on glass slides coated
with 3-aminopropyl-triethoxysilane (APES; Sigma, Poole,
Dorset, UK) and were baked for 30 min at 56–60°C, before
being dewaxed in Clearene (Surgipath Europe, Peterbor-
ough, UK). The tissue was rehydrated by sequential immer-
sion in 100% and 50% ethanol to distilled water. Tissue
sections were subjected to heat antigen retrieval for 3 min
in citrate buffer (pH 6) in a pressure cooker, and after cool-
ing were incubated for 5 min in 0.3% (v/v) hydrogen perox-
ide. Subsequently, sections were washed in tap water and
TBS (pH 7.45). Before incubation with IGFBP-3 primary
antibody, sections were exposed to avidin and biotin block-
ing solutions (Vector Laboratories, Burlingame, CA, USA)
for 15 min, respectively. Further blocking was achieved
through exposure to normal rabbit serum (diluted with TBS)
for 30 min at room temperature (20–22°C). Primary anti-
body was applied and incubated overnight at 4°C (18
hours). After washing with TBS, biotinylated rabbit anti-
goat secondary antibody, together with the Strept-AB
Complex/HRP (0377, DAKO, Glostrup, Denmark) was
applied for 30 min at room temperature. Staining was
revealed by development in the chromogen 3,3-diami-
nobenzidine tetrahydrochloride (DAB) for 5–10 min before
counterstaining with haematoxylin in preparation for
mounting.
Immunostaining was assessed with a Zeiss Axioskop
microscope with a 40× Achrostigmat lens (× 400 overall
magnification) and a field diameter of 0.46 mm. In the neo-
plastic cell population for IDC and DCIS, the degree of
staining intensity and the proportion of cells with IGFBP-3
immunoreactivity in the nucleus and cytoplasm were
graded semi-quantitatively to produce an intensity distribu-
tion score for each localisation, with invasive and pre-inva-
sive components given separate scores. Initial scoring was
of 10 HPFs; however, in view of the homogeneous staining,
this was reduced to 5 HPFs. Sections were scored inde-
pendently by two observers and were scored as follows:
negative (0), weak/moderately positive (1+) or strongly
positive (2+), with DCIS and invasive components scored
independently. Scores were assessed as a continuum for
the purposes of statistical correlation, unless otherwise
stated.
Statistical analysis
Data were analysed with the SPSS 10.0 for Windows sta-
tistics software and summarised with descriptive statistics.
The associations between IGFBP-3 and patient character-
istics were assessed with the Spearman non-parametric
test for continuous variables and the χ2 test for categorical
factors. Analyses of survival data were performed with the
log-rank test and the Cox regression model, and survival
curves were computed with the Kaplan-Meier method. For
IGFBP-3, univariate and multivariate analyses were per-
formed, the latter adjusting for NPI score and treatment
received (tamoxifen/chemotherapy/none). Because the
NPI is based on nodal involvement, on tumour size and on
grade, patients (n = 11) with non-evaluable lymphadenop-
athy and tumour size were excluded from the multivariate
regression analyses (see Table 3).
Results
IGFBP-3 expression in IDCs and DCIS and their 
relationships to clinicopathological factors
IGFBP-3 immunoreactivity was evaluable in 101 (98%)
cases of IDCs and in 102 cases of DCIS, and scored pos-
itively (1+/2+) as a homogeneous cytoplasmic expression
in 86 (85%) of invasive and 92 (90%) of DCIS components
(Fig. 1; Tables 1 and 2). Strong (2+) IGFBP-3 expression
was seen in 32 invasive breast cancers and 40 cases of
DCIS. A weak/moderate (1+) expression of IGFBP-3 was
evident in the majority of invasive (n = 54) and DCIS (n =
52) components. There was no clear evidence of nuclear
IGFBP-3 expression on IHC in IDC or DCIS. Consistently
low levels of IGFBP-3 were evident throughout the stroma,
without strong expression except in vascular endothelial
cells. A comparison showed that the levels of IGFBP-3
expression in DCIS were similar to those in invasive dis-
ease (Table 2).
We investigated the relationships between the levels of
IGFBP-3 expression and clinicopathological parameters in
IDCs and DCIS. IGFBP-3 scores were analysed as a
continuum for the purposes of statistical analysis. There
were no significant associations (where data was assessed
as a continuum) between IGFBP-3 and established prog-
nostic indicators in invasive disease (lymph node involve-
ment, increasing tumour size, increasing tumour
histological grade, ER negativity [quick-score 0–8], lym-
phovascular invasion and NPI). There was a possible trend
between increasing IGFBP-3 levels and increasing cellular
proliferation (Ki67) in invasive disease (Spearman correla-
tion coefficient [cc] 0.166, P = 0.096) (where assessed as
a continuum) that was not observed in DCIS (P = 0.8) (dataBreast Cancer Research    Vol 7 No 1    Vestey et al.
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not shown), or where Ki67 was categorised as <10% ver-
sus ≥ 10% (Table 1). A comparison of categorical IGFBP-
3 expression with ER-positive (quick-score 4–8) and ER-
negative (quick-score 0–3) IDCs showed a trend (P  =
0.06) with ER-negative tumours and HER-2-positive inva-
sive tumours (P = 0.065) (Table 1). In Table 1, 94% (33 of
35) of ER-negative cancers expressed either 1+ or 2+
IGFBP-3 versus 80% of ER-positive tumours (χ2 test, P =
0.06). Similarly, 94% (15 of 16) of HER-2-positive tumours
expressed IGFBP-3 (1+/2+) versus 84% of HER-2-nega-
tive cancers (P = 0.065).
There were no associations between IGFBP-3 expression
and pathological variables on logistic regression in DCIS
(VNPC, HER-2 expression and increased proliferation/
Ki67). A categorical analysis of individual IGFBP-3 scores
(negative versus 1+ versus 2+) in DCIS showed that 97%
(32 of 33) of IGFBP-3-positive DCIS were ER-negative ver-
sus 80% of ER-positive DCIS (P = 0.037) (Table 1). We
demonstrated an inverse correlation between local IGFBP-
3 expression and patient age, in which IGFBP-3 immunore-
activity analysed on a continuum decreased with age (cc -
0.214, P = 0.03) (data not shown); Table 1 shows a signif-
icant association with age (P = 0.04) when IGFBP-3 and
age are analysed categorically in the invasive components,
with a possible trend in DCIS (cc -0.174, P = 0.08) (data
not shown).
Relationships of clinicopathological factors to prognosis 
and the predictive potential of IGFBP-3 expression
Overall survival (OS) and disease-free survival (DFS) were
determined in 87 and 95 patients, respectively, with a
median follow-up of 51 months (range 4–120 months). Dis-
ease relapses (local or distant recurrences) occurred in 30
women; of these, deaths were confirmed in 23 patients,
with 8 suspected deaths in the absence of a recorded mor-
tality date. Locoregional recurrence occurred at a median
duration of 28.5 months (range 3–156 months) from diag-
nosis. Breast cancer-related mortality occurred at a median
of 26 months (range 8–98 months) from presentation. The
mean durations of OS and DFS were 93 months and 87
months, respectively. Four-year DFS and OS were 70%
and 77%, respectively. The relationship of established clin-
icopathological features with OS and DFS were analysed
with Cox's regression analysis (Table 3). Generally poor
prognostic factors such as large tumour size, high tumour
grade, lymphovascular invasion, lymph node metastases,
ER negativity, HER-2 overexpression and NPI were signifi-
cantly associated with decreased OS and DFS. High
tumour proliferation (Ki67 on IHC), although associated
Figure 1
Examples of IGFBP-3 immunoreactivity in infiltrating ductal carcinoma of the breast with concomitant DCIS Examples of IGFBP-3 immunoreactivity in infiltrating ductal carcinoma of the breast with concomitant DCIS. Immunostaining was performed as 
described in the Methods section, and nuclei were counterstained with haematoxylin. (a) A tumour showing cytoplasmic IGFBP-3 expression in inva-
sive ductal cancer. (b) A similar cytoplasmic IGFBP-3 positivity in concomitant DCIS. High-power magnification (original magnification × 400).
Table 2
Immunohistochemical (IHC) scores (0–2) for IGFBP-3 expression in the cytoplasm of invasive ductal cancers and ductal carcinoma 
in situ
Cancer type Total no. of tumours IGFBP-3 IHC score
Negative (0) Weak/moderate (1+) Strong (2+)
I n v a s i v e 1 0 1 1 55 43 2
D C I S 1 0 2 1 05 24 0
Tumour numbers scored (0–2) on immunohistochemistry (IHC) for IGFBP-3 expression in the cytoplasm of invasive cancers and ductal carcinoma 
in situ (DCIS). IHC expression was individually assessed in the nucleus and cytoplasm, and defined as negative (0), weak/moderate (1+) or 
strong (2+). Positivity for IGFBP-3 expression was defined as an IHC score of (1+/2+).Available online http://breast-cancer-research.com/content/7/1/R119
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with a lower percentage of patients remaining disease-free
(DFS) and alive (OS) at 4 years, did not reach statistical
significance.
Univariate and multivariate analysis with the continuous
score variables were used to investigate possible relation-
ships between patient outcome data and levels of expres-
sion for IGFBP-3. IGFBP-3 scores (assessed as a
continuum) were not predictive for OS or DFS after univar-
iate or multivariate analysis (Table 3), adjusted for NPI and
adjuvant treatment (tamoxifen/chemotherapy/none) with
respect to the multivariate analysis. Where IGFBP-3 was
categorised as positive (1+/2+) or negative (0), the Kap-
lan-Meier survival curves (Fig. 2) demonstrate a possible
trend towards a more favourable outcome for IGFBP-3-
negative tumours, although this failed to reach statistical
significance for OS (P  = 0.168) or DFS (P  = 0.269),
perhaps related in part to the small numbers of IGFBP-3-
negative tumours observed in this study.
Discussion
IGFBP-3 has direct intrinsic actions, as well as regulating
IGFs to influence cellular growth, survival and apoptosis of
breast epithelial cells. Breast cancer cells typically express
several IGFBPs, with IGFBP-2, IGFBP-3, IGFBP-4 and
IGFBP-5 being observed most often [5,6,22]. Although
previous studies in vivo have suggested a tumour-related
upregulation of IGFBP-3 levels, clinical studies have yet to
determine IGFBP-3 epithelial protein expression in breast
cancers; this is the first IHC study. IHC of tissue micro-
assays confirms a tumour-specific upregulation of IGFBP-
5 and IGFBP-2 in primary breast cancers and their lymph
node metastases [6]. The significance of these findings in
the context of a decreased mRNA expression for IGFBP-5
and IGFBP-2, respectively, highlights the value and clinical
contribution of an immunohistochemical evaluation[6]. Fur-
thermore, a tumour-specific pathway is implicated, with
negligible levels of IGFBP-5 and IGFBP-2 in normal breast
epithelial cells[6,39,40]. Increasing levels of IGFBP-3 in
breast cancer tissues correlate with poor prognostic
features, as demonstrated in four studies in vivo through
enzyme-linked immunosorbent assay and immunoradiomet-
ric assay [23-26]. The admixture of tumour with normal and
stromal breast tissue is a feature of both quantitative meth-
ods with possible limitations regarding the evaluation of a
predominant tumour-specific epithelial protein.
No studies have yet clarified IGFBP-3 expression on IHC in
invasive breast cancers in comparison with DCIS, although
there has been a limited review of colorectal carcinomas
and normal colonic mucosa[9]. This study suggests that
most breast cancers express epithelial IGFBP-3 (1+/2+),
mostly with a weak/moderate immunoreactivity (1+). Fewer
tumours expressed IGFBP-3 strongly (2+) and it was evi-
dent more frequently in DCIS. Similar genomic aberrations
may occur in DCIS and IDC to highlight possible similari-
ties in protein expression [41,42]. This study, in large part,
shows a consistent similarity in the levels of IGFBP-3
expression in DCIS and IDC (cc 0.789; P < 0.001) (Table
2).
Nuclear localisation of IGFBP-3 has been described in sev-
eral cell lines in vitro, including breast cancer cells[20,21].
This observation is supported by the direct interaction of
IGFBP-3 with the nuclear receptor retinoid X receptor and
the ability of IGFBP-3 to act as a nuclear-import carrier for
IGF-I[20,22,43]. This has raised considerable interest in
the potential nuclear actions of IGFBP-3 and its functional
Figure 2
The relationship of IGFBP-3 to disease-free survival (DFS) and overall  survival (OS) The relationship of IGFBP-3 to disease-free survival (DFS) and overall 
survival (OS). DFS (a) and OS (b) curves according to IGFBP-3-posi-
tive (1+/2+) and IGFBP-3-negative (0) breast cancers. The patient 
numbers reflect the exclusion of six local tumour recurrences as 
described in the Methods section, and include only recorded deaths in 
23 patients. The P values are given for the log ranks.
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implications. There have been very few observations of
nuclear localisation of IGFBPs in vivo, with cytoplasmic
IGFBP-5 expression in breast tumours and, similarly, cyto-
plasmic IGFBP-3 in normal colonic crypts[6,9]. Moreover,
there is further evidence in vitro suggesting that IGFBP-3
growth modulation might be independent of nuclear trans-
location[19]. In the 101 samples of IDC and DCIS
analysed in the study, we observed no evidence of nuclear
staining for IGFBP-3.
IGFBP-3 modulates cellular proliferation with dual actions
that either enhance IGFs or inhibit their actions. By con-
trast, in IGF-unresponsive Hs578T breast cancer cells,
IGFBP-3 is predominantly growth-inhibitory and pro-apop-
totic[11,27]. Similarly, there is a potential for IGFBP-3 to
switch its action on cell survival in Hs578T cells through
changes in the extracellular matrix, with a clear reversal of
IGFBP-3 accentuation of apoptosis when cells are
changed from being grown on either plastic, collagen or
laminin to fibronectin[27]. This suggests that IGFBP-3
might be preferentially activating integrin receptors that
bind fibronectin in a pro-survival growth stimulatory path-
way[44,45]. Upregulation of fibronectin expression is a fea-
ture of breast cancer metastases and poor prognostic
tumours, with evidence of IGFBP-3 binding to this mesen-
chymal extracellular matrix glycoprotein[29,46,47].
Table 3
Relationships between clinicopathological criteria, cytoplasmic IGFBP-3 and patient outcome
Variable Univariate analysis Multivariate analysis
95% CI P 95% CI P
Overall survival
Age 0.99–1.04 0.4 0.98–2.90 0.009
Lymph node status (+/-) 2.79–153.9 0.004 2.65–161 0.003
Invasive tumour grade (I, II, III) 1.27–4.93 0.002 1.14–4.62 0.002
Tumour size 1.02–1.05 <0.001 1.02–1.05 <0.001
NPI 1.48–3.36 <0.001 1.39–3.32 <0.001
ER (quick-score) 0.66–0.92 0.002 0.68–0.98 0.03
HER-2 IHC score 0.94–2.02 0.04 0.76–1.95 0.56
Ki67 proliferative index 0.99–1.00 0.4 0.99–1.00 0.65
Lymphovascular invasion (+/-) 1.46–9.38 0.006 0.89–6.69 0.08
IGFBP-3 IHC score 0.62–2.01 0.719 0.59–2.50 0.592
Disease-free survival
Age 0.97–1.02 0.9 0.99–1.06 0.06
Lymph node status (+/-) 2.29–25.3 <0.001 2.06–25.6 0.002
Invasive tumour grade (I, II, III) 1.48–5.38 0.005 1.36–5.11 0.006
Tumour size 1.02–1.04 <0.001 1.02–1.04 <0.001
NPI 1.46–3.17 <0.001 1.38–3.15 <0.001
ER (quick-score) 0.66–0.89 0.001 0.68–0.95 0.01
HER-2 IHC score 1.04–1.92 0.02 0.95–1.87 0.2
Ki67 proliferative index 0.99–1.00 0.2 0.99–1.00 0.3
Lymphovascular invasion (+/-) 1.63–6.95 0.002 1.09–6.65 0.03
IGFBP-3 IHC score 0.61–1.71 0.922 0.57–1.90 0.896
Confidence intervals (CI) and P values are given for the results of both the univariate and multivariate analyses. The multivariate analysis is 
adjusted for Nottingham Prognostic Index (NPI) (nodes, grade and size) and treatment (tamoxifen/chemotherapy/none). Data for univariate 
analysis were evaluable in 95 patients (reflecting the exclusion of six local tumour recurrences as described in the Methods section) and included 
a multivariate analysis on 84 cases that excluded non-evaluable NPI in 11 patients. All clinicopathological variables and cytoplasmic IGFBP-3 
immunohistochemistry (IHC) scores were analysed as a continuum, with lymph node status and lymphovascular invasion assessed as present or 
absent. Significant P values (P < 0.05) are indicated in bold.
ER, oestrogen receptor.Available online http://breast-cancer-research.com/content/7/1/R119
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Tumour-related upregulation of IGFBP-3 levels in aggres-
sive breast cancers is only partly explicable by the
described findings in vitro.
Evidence is accumulating that IGFBP-3 is a potential
mitogen that interacts with EGFR and HER-2 signalling
pathways [16-18,28]. The potential to switch the IGFBP-3
action on cell growth suggests that IGFBP-3 has a role in
malignant progression of breast cancer cells with insensi-
tivity to IGFBP-3 growth inhibition through the expression
of oncogenic Ras [17]. This is further supported by four
clinical studies of breast tumours, including the present
study demonstrating a spectrum of increased IGFBP-3 lev-
els, with the highest expression indicative of a more malig-
nant phenotype [23-26]. Increasing passages of T47D
cells switch their response to IGFBP-3 with increasing tum-
origenicity, although initially growth-inhibited by this bind-
ing protein [18]. Dual growth modulation by IGFBP-3 is
demonstrated in MCF10A cells, in which IGFBP-3
changes from a growth inhibitor to a mitogen through Ras-
induced malignant transformation and activation of Ras-
p44/42 MAPK [16,17]. Normal breast epithelial MCF10A
cells exposed to increasing doses of IGFBP-3 show a sim-
ilar biphasic response, with preliminary growth inhibition
followed by IGFBP-3 mitogenicity in the context of an IGF-
I receptor antagonist, or a serine phosphorylation domain
peptide (SPD, a non-IGF binding peptide), to verify these
IGF-independent effects[11,48]. LNCaP prostate cancer
cells are similarly growth-stimulated by IGFBP-3 independ-
ently of IGFs [49].
In this study we found a possible association with
increased proliferation, together with other adverse prog-
nostic features such as ER negativity and HER-2 overex-
pression. Elevated IGFBP-3 expression might therefore
suggest an abundance of IGFs sequestered by the binding
protein, with further implications of an IGF-independent
mitogenic role. IGFBP-3 mitogenicity may also relate to
candidate proteases, such as cathepsin D, prostate-spe-
cific antigen and matrix metalloproteinases, with IGFBP-3
proteolysis potentially releasing IGFs to enhance their
mitogenicity. The precise mechanism for this regulation
remains unknown because studies so far have shown no
clear correlations between IGFBP-3 and these proteins in
tissue extracts.
This study suggests an association between IGFBP-3
expression and ER negativity and confirms previous find-
ings in vivo [24,25]. Clearly, there is a significant synergism
between the ER and the IGFs in breast cancer cells [1-3].
Many members of the IGF system are under transcriptional
control of the ER, with IGF-I similarly enhancing the tran-
scriptional activity of ER[1,2]. Oestrogens transcriptionally
downregulate IGFBPs in breast tissue and increase
IGFBP-3 proteases, which may in part explain the inverse
association between IGFBP-3 and ER expression [24,25],
as well as perhaps reflecting the disruption of common
pathways characteristic of poor prognostic tumours
[2,50,51]. HER-2 overexpression predicts aggressive and
poor prognostic breast tumours that are likely to be ER
negative and tamoxifen resistant[52]. Recent evidence in
vitro suggests a functional interaction between the IGF-I
receptor and HER-2, with the potential for IGFBP-3 to
modulate this response[53,54]. Our finding of an associa-
tion between IGFBP-3 and HER-2 expression is preliminary
and, although based on a limited number of HER-2-positive
tumours, may suggest a role for HER-2 in IGFBP-3 growth
modulation. In vitro, IGFBP-3 promotes EGF in HER-2-
overexpressing T47D and Hs578T breast cancer cells
[18,28,30]. Ageing is associated with profound changes in
the growth hormone/IGF regulatory pathways, with dimin-
ished circulating IGFBP-3, as well as decreased tissue lev-
els previously observed in vivo and confirmed in this study
[2,25].
Although high levels of IGFBP-3 in breast cancers are
associated with poor prognostic features of the tumour,
few studies have substantiated any significant implications
on patient outcome[24,25]. Tissue IGFBP-3 concentra-
tions have been reported to predict a reduced OS, but this
was not associated with breast cancer recurrence [25].
This study suggests that IGFBP-3 expression in breast
cancers might be associated with a shorter OS and DFS,
although few patients were negative for IGFBP-3 expres-
sion. Other studies, including the present one, show a con-
sistent negative association between IGFBP-3 expression
and favourable prognostic markers underlining the poten-
tial importance of this pathway in tumorigenesis [23-26].
IGFBP-3 regulates breast cancer epithelial growth through
IGF-dependent and IGF-independent pathways that
involve both growth inhibition and enhanced apoptosis with
the potential to switch to growth stimulatory pathways
interacting with EGFR, HER-2 and fibronectin. Defining
these mechanisms merits further studies in vitro and in
vivo.
Conclusion
IGFBP-3 is important in tumorigenesis because of its
effects on cellular proliferation, survival and apoptosis. We
have demonstrated a tumour-associated upregulation of
cytoplasmic IGFBP-3 epithelial expression in invasive and
non-invasive breast cancers, with similar patterns of immu-
noreactivity. Despite evidence in vitro and functional impli-
cations, no nuclear IGFBP-3 expression was detectable on
IHC. Invasive breast cancers expressing IGFBP-3 showed
an association with poor prognostic features including
increased proliferation, ER negativity and HER-2 overex-
pression, with possible implications for patient outcome.
IGFBP-3 is a growth modulator with the potential to switchBreast Cancer Research    Vol 7 No 1    Vestey et al.
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from a growth inhibitor to a mitogen that interacts with the
EGFR family.
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